The aim of European Urology Focus (EU Focus) is to encompass the whole spectrum of urology. The journal publishes papers on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcomes basic and translational research articles in the field of urological diseases.
Besides original research articles and systematic reviews, which are the backbone of the journal, EU Focus publishes "Point of Focus" debates which cover controversial topics from a pro/con standpoint. The journal also publishes "Clinical Trial Updates" focusing on an ongoing trial, and the "Grey Zone", which sheds light on areas for which guideline recommendations are difficult to make, because of the absence of data. In addition, the "Clinical Consultation Guide" discusses hot topics from a clinician's point of view. The journal also includes "Mini-Reviews", which allow the summary of a certain topic in no more than 1000 words.
In the summer of 2017, a new editorial team was appointed. The composition of the team reflects the diversity of the journal: Derya Tilki (Germany), and Peter Black (Canada) are primarily responsible for papers on oncology, while Richard Lee (USA) and Malte Rieken (Switzerland), will handle papers in the area of benign disease. Cathy Pierce (USA) is the Managing Editor, sharing her long-standing experience gained with European Urology.EU Focus was started in 2015 and was the first sister journal to European Urology. The philosophy of European Urology to strive for the highest-quality scientific articles is also key for EU Focus. EU Focus publishes 6 issues per year in electronic format only. The journal is indexed in PubMed.
European Urology Focus
For the full Guide for Authors, please use the link: https://www.elsevier.com/journals/european-urology/0302-2838/guide-for-authors
SKIP TO PARAGRAPHEuropean Urology Focus – General Information
Authorship Responsibility, Financial Disclosure and Acknowledgment Form
Clinical Consultation Guide
Point of Focus Debate (For/Against)
Clinical Trial Update
European Urology Focus – General Information
European Urology Focus (EU Focus) is a sister journal to European Urology and an official publication of the European Association of Urology (EAU), a scientific society with more than 15,000 members from 120 countries worldwide. EU Focus is available online and reaches over 20,000 readers.EU Focus publishes original articles, case debates, clinical practice points, opinion piece editorials and topical reviews on all urological issues. The editorial team welcome basic and translational research articles in the field of urological diseases.
Authors may be solicited by the Editor directly, and may approach the editorial office for advice or guidance before submission.All submitted manuscripts are peer-reviewed by a panel of experts before being considered for publication.
EU Focus is published 6 times per year in an electronic format. Each issue includes a series of invited themed reviews, together with original reports, correspondence and introductory editorials.Access to EU Focus articles is available through http://europeanurology.com/eu-focus and http://www.sciencedirect.com/science/journal/24054569
The open access publication fee for this journal is USD 3000, excluding taxes. Learn more about Elsevier's pricing policy: https://www.elsevier.com/openaccesspricing.EU Focus articles are listed on the PubMed database.
Manuscripts should be submitted online via the European Urology Focus online manuscript submission and review system at https://www.editorialmanager.com/eufocusStatements in articles or opinions expressed by any contributor in any article are not the responsibility of the editors or the publishers. The publisher is not responsible for the loss of manuscripts through circumstances beyond its control.
Accepted manuscripts will be copyedited to make sure they conform to the journal's style. The final version of the manuscript following copyediting will be sent back to the author only if specific queries need clarification.
Authorship Responsibility, Financial Disclosure and Acknowledgment Form
Completion and inclusion of the Authorship Responsibility, Financial Disclosure and Acknowledgment Form is an obligatory step of the submission process for all articles. If the form is not completed as instructed below, the manuscript will not be considered for peer review.The corresponding author must submit the above mentioned completed form on behalf of all co-authors, if any. Download form authorship form here.
The corresponding author must take responsibility for the integrity of the work as a whole, from inception to published article. Each collaborating author should haveparticipated sufficiently in the work to take public responsibility for appropriate portions of the content. Authorship credit should be based on: substantialcontributions to conception and design, acquisition of data, analysis and interpretation of data, drafting of the article or revising it critically for importantintellectual content, statistical analysis, obtaining funding, administrative, technical or material support, supervision and any other specifics to be declared atpublication. The corresponding author is obliged to indicate the co-authors contribution to the manuscript in the appropriate field in the said form.Each co-author's specific contribution for reports of original data and systematic reviews will be included with the published manuscript.Each field may include more than one author.
Role of the Corresponding Author
The corresponding author will serve on behalf of all co-authors as the primary correspondent with the editorial office during the submission and review process. If themanuscript is accepted, the corresponding author will review an edited typescript and proof and will be identified as the corresponding author in the publishedarticle. The corresponding author is responsible for ensuring that all information included in the Authorship Responsibility, Financial Disclosure and Funding Supportform and the Acknowledgment section, if any, is complete and has been agreed on by all authors. ''Acknowledgment'' is the general term for the list of contributions,credits, and other information included at the end of the text of a manuscript before the references.
If authorship is attributed to a group (either solely or in addition to one or more individual authors), all members of the group must meet the full criteria andrequirements for authorship as described above. If that is not the case, a group must designate one or more individuals as authors or members of a writing group whomeet full authorship criteria and requirements. Other group members who are not authors may be listed in an Acknowledgment.
A conflict of interest may exist when an author (or the author's institution or employer) has financial or personal relationships or affiliations that could influence(or bias) the author's decisions, work, or manuscript.
Declaration of Interest and Financial Disclosures
Authors are expected to provide detailed information about all relevant financial interests and relationships or financial conflicts (e.g., employment/affiliation,grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), particularly thosepresent at the time the research was conducted and through publication, as well as other financial interests (such as patent applications in preparation), thatrepresent potential future financial gain.For example, authors of a manuscript about prostate cancer should report all financial relationships they have with all manufacturers of products used in themanagement of prostate cancer, not only those relationships with companies whose specific products are mentioned in the manuscript.
Although many universities and other institutions have established policies and thresholds for reporting financial interests and other conflicts of interest, EuropeanUrology Focus requires complete disclosure of all relevant financial relationships and potential financial conflicts of interest, regardless of amount or value.Downloads: authorship form.
These manuscripts typically report on basic and translational research, epidemiology, pathophysiology, diagnosis, medical or surgical treatment, and minimally invasive therapy related to urologic diseases.Each manuscript should clearly state an objective or hypothesis; the design and methods (including the study setting and dates, patients or participants with inclusion and exclusion criteria and/or participation or response rates, or data sources, and how these were selected for the study); the essential features of any interventions; the main outcome measures; the main results of the study; a discussion section placing the results in context with the published literature and addressing study limitations; and the conclusions. Data included in research reports should be as timely and current as possible.
We encourage authors to report outcomes and complications in a structured manner. We advise the use of peer reviewed documents to guide this such as Mitropoulous et al; Reporting and Grading of Complications After Urologic Surgical Procedures: An ad hoc EAU Guidelines Panel Assessment and Recommendations or other recognized reporting structures.Text
Number of references should be limited to 30.
The text of the manuscript should be divided as follows: Introduction; Material (Patients) and Methods; Results; Discussion; Conclusions; Patient Summary.
Maximum word count is 2800, including the abstract but not including the references, tables, figures, or legends. (Abstract Maximum 300 words. Text Maximum 2500)Take Home Message
Two or three sentences (no more than 40 words) summarizing the main message expressed in the article must be uploaded as a separate file.The format of the original article should be as follows:
Provide a structured abstract no longer than 300 words with the following sections: Background; Objective; Design, Setting, and Participants; Intervention (include if there are any); Outcome Measurements and Statistical Analysis; Results and Limitation; Conclusions and Patient Summary (The Patient Summary is an obligatory section of the manuscript. Submissions not including the patient summary will be returned to the corresponding author.)Original Articles must be no longer than 2800 words (300 abstract + 2500 body not including the reference list, tables, figures or legend). References are limited to 30. Please limit tables and figures to 6. Additional tables, figures or appendices may be submitted as supplementary material but will be published online only.
For brevity, parts of the abstract may be written as phrases rather than complete sentences. Each section should include the following content (see abstract structure details below):
- Background: The abstract should begin with a sentence or two explaining the clinical (or other) importance of the study question.
- Objective: State the precise objective or study question addressed in the manuscript (e.g., ''To determine whether. . .''). If more than one objective is addressed, the main objective should be indicated and only key secondary objectives stated.
- Design, Setting, and Participants: Describe the basic design of the study. State the years of the study and the duration of follow-up. Describe the study setting to assist readers to determine the applicability of the report to other circumstances, for example, general community, a primary care or referral center, private or institutional practice, or ambulatory or hospitalized care. State the clinical disorders, important eligibility criteria, and key sociodemographic features of patients. The numbers of participants and how they were selected should be provided. In follow-up studies, the proportion of participants who completed the study must be indicated. In intervention studies, the number of patients withdrawn because of adverse effects should be given. For selection procedures, these terms should be used, if appropriate: random sample (where random refers to a formal, randomized selection in which all eligible individuals have a fixed and usually equal chance of selection); population-based sample; referred sample; consecutive sample; volunteer sample; convenience sample.
- Intervention(s): The essential features of any interventions (surgical or medical) should be described. The nonproprietary drug or device names should be used unless the specific trade name is essential to the study.
- Outcome Measurements and Statistical Analysis: Indicate the primary and secondary study outcome measurement(s) and the main statistical analysis.
- Results and Limitations: The main outcomes of the study should be reported and quantified. Complications or sequelae of the interventions used must be detailed. Particular attention must be paid to estimates of treatment effect and confidence intervals and not just to p-values. All randomized controlled trials should include the results of intention-to-treat analysis, and all surveys should include response rates. Limitations of the study should be acknowledged.
- Conclusions: Provide only conclusions of the study directly supported by the results, along with implications for clinical practice, avoiding speculation and overgeneralization. Indicate whether additional studies are required before the results should be used in usual clinical settings. Give equal emphasis to positive and negative findings of equal scientific merit.
- Patient summary: Please include at the end of the abstract 2-3 short sentences in plain english to describe your findings to a non-medical audience. For example: " In this report we looked at the outcomes from invasive bladder cancer in a large European population. We found that outcomes varied with patient age and treating centre. We conclude that the best outcomes are seen in younger patients treated at high volume hospitals." You will also be asked to include this summary in the "Additional Information" section of the submission process.
Review ArticlesEuropean Urology aims at publishing mainly systematic reviews (and meta-analyses, whenever appropriate). These are reviews that systematically find, select, critique, and synthesize evidence relevant to well defined questions about diagnosis, therapy, and prognosis. Manuscripts reporting systematic review and meta-analysis should comply with the PRISMA statement. Such review articles are in principle solicited by the editorial board. Authors who would like to submit unsolicited systematic review articles should first write to the editorial office describing the content of the review article they wish to submit. Review articles should not be submitted in full without prior approval from the editors.
If you are interested in submitted a review article, please send an outline and structured abstract with the following information to the Editorial Office:1). Title and Author list
2). Systematic Review Search criteria and the preliminary results of this search (including an estimate of how many manuscripts will be included for analysis)3). Primary and secondary outcomes that will be reported (including likely number of persons used to report these data)
4). Null hypothesis and likely conclusionsThe format of the review article should be as follows:
AbstractProvide a structured abstract no longer than 300 words with the following sections: Context, Objective, Evidence Acquisition, Evidence Synthesis, Conclusion and Patient Summary.
Review Articles must be no longer than 4000 words (300 abstract + 3700 body not including the reference list, tables, figures or legend). References are limited to 50. Please limit tables and figures to 6. Additional tables, figures or appendices may be submitted as supplementary material but will be published online only.Context: Include one or two sentences describing the clinical question or issue and its importance in clinical practice or public health.
Objective: State the precise primary objective of the review. Indicate whether the review emphasizes factors such as cause, diagnosis, prognosis, therapy, or prevention and include information about the specific population, intervention, exposure, and tests or outcomes that are being reviewed.Evidence Acquisition: Describe the data sources used, including the search strategies, years searched, and other sources of material, such as subsequent reference searches of retrieved articles. Methods used for quality assessment and inclusion of identified articles should be explained.
Evidence Synthesis: The major findings of the review of the clinical issue or topic should be addressed in an evidence-based, objective, and balanced fashion, with the highest quality evidence available receiving the greatest emphasis.Conclusions: The conclusions should clearly answer the questions posed if applicable, be based on available evidence, and emphasize how clinicians should apply current knowledge.
Patient Summary: Please include at the end of the abstract 2-3 short sentences in plain English to describe your findings to a non-medical audience. For example: " In this report we looked at the outcomes from invasive bladder cancer in a large European population. We found that outcomes varied with patient age and treating centre. We conclude that the best outcomes are seen in younger patients treated at high volume hospitals. " You will also be asked to include this summary in the "Additional Information" section of the submission process.Text
The text of the manuscript should be divided as follows: Introduction, Evidence Acquisition, Evidence Synthesis, Conclusions.Example of Review Article: Hexyl Aminolevulinate–Guided Fluorescence Cystoscopy in the Diagnosis and Follow-up of Patients with Non–Muscle-invasive Bladder Cancer: A Critical Review of the Current Literature
Maximum word count is 4000, including the abstract but not including the references, tables, figures, or legends.Number of references should be limited to 50.Please note that a maximum of 6 tables and/or figures total will be published with the article. Additional figures and tables will be available as supplementary material online only.
Take Home MessageTwo or three sentences (no more than 40 words) summarizing the main message expressed in the article must be uploaded as a separate file.
Clinical Consultation GuideSpecific to European Urology Focus only, this section is aimed at clinical practice points. We ask that these submissions have an unstructured abstract and are no more than 1000 words with 10 references or fewer. One figure or table is welcome. Authors are asked to keep the author list to no more than 3 names.
Point of Focus Debate (For/Against)
Specific to European Urology Focus only, this section is aimed at giving two solicited experts the opportunity to voice their opinion of a given topic assigned by the Editor.We ask that these submissions have an unstructured abstract and are no more than 750 words with 10 references or fewer. One figure or table is welcome. Authors are asked to keep the author list to no more than 3 names. Downloads: Point of Focus Debate (For) - Example (157 KB) Point of Focus Debate (Against) - Example (162 KB)
Clinical Trial UpdateSpecific to European Urology, these are contemporary updates of recent or current clinical trials that are of relevance to that issue of EU Focus. The word limit is typically 750 words, with one figure and table. The text should be structured around the reported trial.
Downloads: Clinical Trial Update - Example (382 KB)
This newly developed format aims at summarizing a novel topic in a brief format. The manuscript body should be no more than 1000 words and include unstructured abstract of 100-150 words (total max word count: 1150 words). The abstract should include a patient summary which describes how the study would apply to a patient population. (Please see below for patient summary instructions). A maximum of 2 tables and/or figures total will be published with the article. Number of references should be limited to 10. Two or three sentences (no more than 40 words) summarizing the main message expressed in the article must be uploaded as a separate file as a "take home message."Patient summary: Please include 2-3 short sentences in plain english at the end of the abstract to describe your findings to a non-medical audience. For example: " In this report we looked at the outcomes from invasive bladder cancer in a large European population. We found that outcomes varied with patient age and treating centre. We conclude that the best outcomes are seen in younger patients treated at high volume hospitals. You will also be asked to include this summary in the "Additional Information" section of the submission process.